FDA Covid-19 Update: Facilitating Diagnostic Test Availability for Asymptomatic Testing and Sample Pooling
FDA has outlined the steps for a test to be authorized for broad screening of asymptomatic individuals.
Read MorePosted by Laurie Bonner | Jun 23, 2020 | Covid 19 |
FDA has outlined the steps for a test to be authorized for broad screening of asymptomatic individuals.
Read MorePosted by Laurie Bonner | Jun 23, 2020 | Covid 19 |
Fulgent Genetics has partnered with a national clinician network on its at-home covid-19 test.
Read MorePosted by Laurie Bonner | Jun 23, 2020 | Covid 19 |
Tru-Immune will measure and quantify the neutralizing capacity of antibodies against the novel coronavirus SARS-CoV-2.
Read MorePosted by Laurie Bonner | Jun 23, 2020 | Uncategorized |
The assay is authorized for use with upper respiratory specimens collected from individuals suspected by their healthcare provider to have covid-19.
Read MorePosted by Laurie Bonner | Jun 23, 2020 | Covid 19 |
Features of the kit include 1.5-hour testing time from preparation to finish, 94-sample capacity, and a limit of detection of 1.2 copies of SARS-CoV-2 RNA per µL.
Read More